CAGRI/SEMA refers to a combination therapy of Cagrilintide (an amylin analog) and Semaglutide (a GLP-1 agonist). A 5mg/5mg formulation indicates the presence of 5mg of each active peptide, often associated with research or specialized compounding.
CAGRI/SEMA 5MG/5MG